Logo

AstraZeneca to Evaluate Compendia's Oncomine Software

Dec 04, 2007
NEW YORK (GenomeWeb News) - AstraZeneca has licensed Compendia Bioscience’s data mining and visualization software, Compendia said today.
 
AstraZeneca will use the company’s Oncomine Concepts Edition software in a year-long pilot program in order to evaluate how it can be used in its cancer research programs.
 
Oncomine combines almost 7,000 proprietary cancer gene signatures with 11,000 gene, drug, and pathway signatures taken from the literature and other public sources, Compendia said.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.